RxDoctor Payments Data

Pulat Pulatov

Family Medicine · Glendale, NYNPI 1437579166

Payments from drug & device makers

$546in general payments, 2019–2025

Across 14 payments — averaging $39.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$125
  • AbbVie$125
  • Lilly USA, LLC$82
  • Dexcom, Inc.$74
  • Irhythm Technologies, Inc.$47
  • Novo Nordisk$32
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$546 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$154,623
Medicare patients
436
Services billed
1,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$44,510
JanuviaSitagliptin Phosphate34$40,725
JardianceEmpagliflozin25$28,304
JanumetSitagliptin Phos/Metformin Hcl19$23,008
EliquisApixaban17$21,391
FarxigaDapagliflozin Propanediol16$19,461
EntrestoSacubitril/Valsartan25$16,528
VascepaIcosapent Ethyl16$9,863
XareltoRivaroxaban13$7,424
Spiriva RespimatTiotropium Bromide11$5,326
Incruse ElliptaUmeclidinium Bromide13$4,307
Cinacalcet Hcl15$3,596
SymbicortBudesonide/Formoterol Fumarate12$2,641
Atorvastatin Calcium223$2,243
Albuterol Sulfate HfaAlbuterol Sulfate52$2,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$44,51027 claims
GSKIncruse Ellipta$14$4,30713 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$1,38394 claims
AbbVieSynthroid$125$1,32923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Glendale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →